Understanding how gut bacteria affect blood sugar after weight loss surgery
Improvement in Glycemic Response After Bariatric Surgery
This study is trying to see how gut bacteria affect blood sugar levels in people after they have weight loss surgery, like gastric bypass or sleeve gastrectomy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Weizmann Institute of Science Academic / other |
| Locations | 2 sites (Rehovot and 1 other locations) |
| Trial ID | NCT05325736 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the role of gut microbiota in the changes in glycemic response following bariatric surgery. By analyzing the microbiome before and after procedures such as sleeve gastrectomy and gastric bypass, the researchers hope to uncover the mechanisms that lead to metabolic improvements. The findings could identify new targets for pharmacological interventions, potentially reducing the need for surgical options. The study addresses previous methodological limitations in microbiome research related to bariatric surgery.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 18-70 who are planning to undergo bariatric surgery or cholecystectomy.
Not a fit: Patients with a history of previous bariatric surgery, type 1 diabetes, or chronic gastrointestinal diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new treatments that improve blood sugar control without the need for surgery.
How similar studies have performed: Previous studies have explored the microbiome's role in metabolic changes after bariatric surgery, but this study aims to address methodological shortcomings, making it a potentially novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * candidates of bariatric surgery or cholecystectomy * age 18-70 * male/female Exclusion Criteria: * previous bariatric surgery * type 1 diabetes * antibiotic treatment 3 months prior to the study * probiotic treatment 3 months prior to the study * chronic disease - gastrointestinal disease, malignancy, psychiatric disorder, endocrinologic disorders * any pathologic findings during endoscopy * participants who will suffer from a post-operation complication
Where this trial is running
Rehovot and 1 other locations
- Weizmann Institute of Science — Rehovot, Israel (Recruiting)
- Souraski medical center — Tel Aviv, Israel (Recruiting)
Study contacts
- Principal investigator: Danit Dayan, MD — Souraski medical center
- Study coordinator: Avner Leshem, MD
- Email: avner.leshem@weizmann.ac.il
- Phone: +972547487555
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.